JD Vance Pushes Debunked Claim Of Fentanyl-Laced Marijuana Despite New Harvard-Led Study Findings
How to deal with risk factor of inadvertent fentanyl in marijuana? Take weed off street corners, lab test and regulate it, says expert. read more
Read More
After Gold’s ‘Moment In The Sun,’ It’s Now Silver’s Turn: These ETFs Linked To The Shiny Metal Are Rising In Thursday’s Pre Market
As global tensions and market uncertainty continue to escalate, silver prices are experiencing a significant rise. This surge has resulted in notable gains for silver-linked ETFs in recent trading sessions. read more
JPMorgan Vs. Global X: Which High-Yield Dividend ETF Is The Better Pick As Fed Cuts Interest Rates?
High-yield dividend ETFs are back with Fed’s interest rate cuts. JPMorgan Equity Premium Income has a volatile strategy while Global X Super Dividend offers stability. Choose based on income needs and risk tolerance in a changing economy. read more
Nvidia Chases Growth in India: AI Partnerships With Reliance, Infosys, Wipro, Expanding into Robotics And Key Industries
Nvidia Corp (NASDAQ: NVDA) partners with Indian firms to expand AI chips deployment and drive AI adoption in healthcare, agriculture, and manufacturing. read more
Social Media Reacts As Juul Users Get Compensation Through Venmo After $300M Class-Action Settlements: ‘Vaping Actually Paid Off’
The funds are being distributed among 842,000 valid claims, with payouts varying based on the amount claimants could prove they spent on Juul products. read more
How To Earn $500 A Month From Weyerhaeuser Stock Ahead Of Q3 Earnings
Weyerhaeuser Company will release earnings results for its third quarter, after the closing bell on Thursday, Oct. 24. read more
ServiceNow Analysts Boost Their Forecasts Following Upbeat Q3 Earnings
Latest Ratings for NOW DateFirmActionFromTo Jan 2022Canaccord GenuityMaintainsBuy Jan 2022BMO CapitalMaintainsOutperform Jan 2022Morgan StanleyMaintainsOverweight View More Analyst Ratings for NOW View the Latest Analyst Ratings read more
Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: ‘Wait For A Pullback’
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said no to Nextracker. “Nextracker’s a mistake that I made,” he added. read more